Diaz Belmont A, Dominguez Henkel R, Uribe Ancira F
Clínica para la Atención a Problemas Relacionados con el Alcohol, Hospital General de México, S.Sa.
An Med Interna. 1996 Jan;13(1):9-15.
The improvements in the knowledge of the action of ethanol over the hepatic cell, its direct action over the cell, and the intracytoplasmatic structures membranes, point out the possibilities of use of sulfo-adenosil-L-metionina (SAMe); as an util drug inn the treatment of the altered metilation reactions, that take place in those membranes, facilitating their physiological functions. The primary end point in this study was to demonstrate the therapeutic worth os SAMe, by parenteral route in 45 patients with alcoholic liver disease, which were determined by clinical laboratory and hepatic function test, label qith 32 points or more of the discriminatory function index. Divided into two groups, placebo-SAMe, randomized, double blind. As well as total plasmatic and reduced glutation and lipoperoxidation index, indirect form as malondehaldehyde. Were determined at the first visit anf after 8 and 15 days of treatment. Comparing the results of both groups there were a significative favorable results for the group treatment with SAMe and this confirms the utility of this drug in the treatment of patients with alcoholic liver disease with a discriminatory function index (Maddrey index), of 32 points or more.
乙醇对肝细胞作用的认识有所进步，其对细胞及胞质内结构膜的直接作用，指出了使用硫代腺苷-L-蛋氨酸（SAMe）的可能性；作为一种实用药物，用于治疗在那些膜中发生的甲基化反应改变，促进其生理功能。本研究的主要终点是通过肠胃外途径，在45例酒精性肝病患者中证明SAMe的治疗价值，这些患者通过临床实验室和肝功能测试确定，鉴别功能指数达到32分或更高。分为两组，安慰剂-SAMe组，随机、双盲。以及总血浆和还原型谷胱甘肽和脂质过氧化指数，以丙二醛的间接形式表示。在首次就诊时以及治疗8天和15天后进行测定。比较两组结果，SAMe治疗组有显著的有利结果，这证实了该药物在治疗鉴别功能指数（马德雷指数）为32分或更高的酒精性肝病患者中的效用。
